Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection
| Status: | Terminated |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | November 2012 |
| End Date: | January 2014 |
Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection.
This study plans to learn more about the role of 2 blood tests in predicting who might
develop a blood clot in their arm or leg after major surgery. The investigators know that
patients who have cancer and major surgery have a higher than normal risk of getting blood
clots in the veins of their arms or legs. This can be very dangerous because the clot can
move into your lungs.
develop a blood clot in their arm or leg after major surgery. The investigators know that
patients who have cancer and major surgery have a higher than normal risk of getting blood
clots in the veins of their arms or legs. This can be very dangerous because the clot can
move into your lungs.
Venous Thromboembolism (VTE) after cancer surgery hospitalization is the most common cause
of death at 30 days after cancer surgery, and is a significant source of patient morbidity
and health care cost. Pharmacoprophylaxis has proven efficacy in preventing post-discharge
VTE in surgical cancer patients, but perceived risks and costs pose barriers to widespread
adoption by clinicians. Risk stratification of this patient population is necessary to allow
appropriate prescription of prophylaxis to the highest risk patients. Can the investigators
develop a risk stratification model that includes a readily available laboratory test, the
thromboelastogram with or without platelet mapping?
of death at 30 days after cancer surgery, and is a significant source of patient morbidity
and health care cost. Pharmacoprophylaxis has proven efficacy in preventing post-discharge
VTE in surgical cancer patients, but perceived risks and costs pose barriers to widespread
adoption by clinicians. Risk stratification of this patient population is necessary to allow
appropriate prescription of prophylaxis to the highest risk patients. Can the investigators
develop a risk stratification model that includes a readily available laboratory test, the
thromboelastogram with or without platelet mapping?
Inclusion Criteria:
- subjects who are having primary, open resection surgery of gastrointestinal or
bladder cancer
Exclusion Criteria:
- currently receiving anticoagulation therapy
- pregnant
We found this trial at
1
site
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
